Haemonetics Corporation P/E Ratio 2009–2026
Haemonetics Corporation reported 27.49 of price-to-earnings ratio for fiscal 2026. That was 43.2% higher than fiscal 2025. Compared with fiscal 2021, the change was -36.6%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2026 | 27.49 | +43.2% |
| FY 2025 | 19.20 | -48.5% |
| FY 2024 | 37.27 | +0.9% |
| FY 2023 | 36.94 | -38.8% |
| FY 2022 | 60.32 | +39.0% |
| FY 2021 | 43.39 | -35.6% |
| FY 2020 | 67.34 | -19.9% |
| FY 2019 | 84.12 | -2.3% |
| FY 2018 | 86.07 | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
| FY 2015 | 140.37 | +188.6% |
| FY 2014 | 48.64 | -13.6% |
| FY 2013 | 56.30 | +110.1% |
| FY 2012 | 26.80 | +19.1% |
| FY 2011 | 22.50 | -12.9% |
| FY 2010 | 25.83 | +6.5% |
| FY 2009 | 24.26 | — |
Source: Haemonetics Corporation SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open HAE 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Haemonetics Corporation reported 27.49 of price-to-earnings ratio for fiscal 2026. That was 43.2% higher than fiscal 2025. Compared with fiscal 2021, the change was -36.6%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Haemonetics Corporation
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeHaemonetics Corporation — frequently asked questions
What is Haemonetics Corporation's price-to-earnings ratio?
Haemonetics Corporation (HAE) reported price-to-earnings ratio of 27.49 for fiscal year 2026, per its SEC filings.
How has Haemonetics Corporation's price-to-earnings ratio changed over time?
Between fiscal 2009 and 2026, HAE's price-to-earnings ratio grew at roughly 0.7% per year (compound annual rate), from 24.26 to 27.49.
Where does this data come from?
Figures are computed from Haemonetics Corporation's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More HAE financial history
Full HAE fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →